Slide MOLECULAR CELLULAR AND GENOMICS BIOMEDICINE José María Millán Salvador





The Research Group on Molecular, Cellular and Genomic Biomedicine (BMCG) was accredited in 2010 and it is composed of a total of 21 researchers, ten of them belonging to the joint Unit for Rare Diseases CIPF_IIS La Fe. It is led by Dr. José M. Millán. The group is multidisciplinary and is made up of ophthalmologists, ENT doctors, geneticists, molecular biologists and biochemists, and participates as a member in the CIBER of Rare Diseases. Its objective is to deepen the knowledge of the physiology, genetics and clinics of diseases that fundamentally affect the organs of vision and hearing but also neuromuscular and neurodegenerative organs, seeking the immediate application of the results of this research to the clinical practice for the benefit of the patient.

Presentation

Get to know us better

Research Staff

The people who make it all possible

Eloisa Jantus Lewintre

Carlos Camps Herrero

Silvia Calabuig Fariñas

Macarena Ferrero Gimeno

Jose Vicente Bagan Sebastian

Ricardo Guijarro Jorge

Miguel Martorell 

Ana Blasco Cordellat

Alfonso Berrocal Jaime

Vega Iranzo González-cruz

Eva Escorihuela Alares

Andrea Moreno Manuel

Susana Torres Martinez

Publications

Our scientific contributions

dPCR application in liquid biopsies: divide and conquer
A. MORENO-MANUEL, S. CALABUIG-FARINAS, A. OBRADOR-HEVIA, A. BLASCO, A. FERNANDEZ-DIAZ, R. SIRERA, C. CAMPS and E. JANTUS-LEWINTRE
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021 Jan,  Vol. 21,  pag. 3-15

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
A. MORENO-MANUEL, E. JANTUS-LEWINTRE, I. SIMOES, F. ARANDA, S. CALABUIG-FARINAS, E. CARRERAS, S. ZUNIGA, Y. SAENGER, R. ROSELL, C. CAMPS, F. LOZANO and R. SIRERA
Translational Lung Cancer Research, 2020 Aug,  Vol. 9,  pag. 1074

Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice.
Camps C, Badia X, García-Campelo R, García-Foncillas J, López R, Massuti B, Provencio M, Salazar R, Virizuela J and Guillem V
Jco Oncology Practice, 2020 Mar,  Vol. 16,  pag. e298-e305

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.
Chaib I, Cai X, Llige D, Santarpia M, Jantus-Lewintre E, Filipska M, Pedraz C, Cui J, Yang J, Miao J, Sun R, Bracht JWP, Ito M, Codony-Servat J, Karachaliou N, Aguilar A, Rosell R and Cao P
Annals of Translational Medicine, 2019 Nov,  Vol. 7,  pag. 651-651

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer
Herreros-Pomares A, de-Maya-Girones JD, Calabuig-Fariñas S, Lucas R, Martínez A, Pardo-Sánchez JM, Alonso S, Blasco A, Guijarro R, Martorell M, Escorihuela E, Chiara MD, Duréndez E, Gandía C, Forteza J, Sirera R, Jantus-Lewintre E, Farràs R and Camps C
Cell Death & Disease, 2019 Sep,  Vol. 10,  pag. 660-660

FUNDING

Thank you for supporting us